share_log

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $52

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $52

HC Wainwright & Co.维持对SpringWorks Therapeutics的买入,将目标股价下调至52美元
Benzinga ·  2023/11/20 06:22

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and lowers the price target from $58 to $52.

HC Wainwright & Co. 分析师罗伯特·伯恩斯维持SpringWorks Therapeutics(纳斯达克股票代码:SWTX)的买入,并将目标股价从58美元下调至52美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发